BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC):Interim analysis (IA) of a randomized phase II study
Year: 2024
Type: article
Authors: Kalinka, E., Bahce, I., Navarro Mendivil, A.F., Ready, N., Chu, Q.S-C., Sugawara, S., Sibille, A., Provencio Pulla, M., Johnson, M.L., Hiltermann, J.T.J.N., Ciuleanu, T-E., Dziadziuszko, R., Santo, A., Zhang, Y., Liu, Y., Sarmiento, R., Tannenbaum-Dvir, S., Ojalvo, L., Wu, J., O’Byrne, K.J.
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W6998861994
FWCI:
Cites:
Cited by:
Related to: